Movers and SHAKERS
Onconova Therapeutics (ONTX)
3Q Report Highlights Clinical Progress
Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company operating in the US. It focuses on discovering and developing novel small molecule product candidates primarily to treat cancer. The company has created a library of targeted agents designed to work against cellular pathways important to cancer cells. Its product candidates are Single-agent IV rigosertib, Oral rigosertib + azacitidine, IV Briciclib, Recilisib, and ON 123300. The key product candidate Rigosertib is a small molecule which blocks cellular signaling by targeting RAS effector pathways.
Robert LeBoyer, Senior Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
3Q21 reported. Onconova Therapeutics reported 3Q21 loss of $3.5 million or $(0.22) per share, compared with our estimated loss of $5.2 million or $(0.33) per share. On its quarterly conference call, the company reviewed clinical progress during the quarter and discussed plans for trials in 2022. Cash balance at the end of the quarter was $59.4 million.
Narazaciclib updates. The company gave an update on the two clinical dose escalation trials for narazaciclib, the new name for ON 123300. The US trial is enrolling its second dose cohort, while the study in China is in its fourth cohort. Data to establish safety and select the dose for Phase 3 is expected in 1H22. This Phase 2 study is expected to include multiple cancer types including patients with ...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.